● Recruiting

Orelabrutinib Plus Rituximab Followed by Maintenance With Orelabrutinib for Relapsed and Refractory Follicular Lymphoma(RR FL)

Condition: Follicular Lymphoma · Relapsed and Refractory Follicular Lymphoma · Sponsor: Sun Yat-sen University

PhasePhase 2

Planned participants32

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

This phase 2 trial studies the efficacy and safety of orelabrutinib plus rituximab followed by maintenance with orelabrutinib for relapsed and refractory follicular lymphoma(RR FL)

This description comes directly from the study's public registry record.

Talk to the study team

Qingqing Cai · 0086-20-87342823 · caiqq@sysucc.org.cn

Always discuss trial participation with your own doctor first.

Locations (3)

Guangdong General Hospital	Guangzhou, Guangdong, China	Recruiting
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University,	Guangzhou, Guangdong, China	Not Yet Recruiting
Sun Yat-sen Universitiy Cancer Center, Sun Yat-Sen University,	Guangzhou, Guangdong, China	Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04989621